Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) Invested Capital (2018 - 2025)

Historic Invested Capital for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $16.6 million.

  • Precision Biosciences' Invested Capital fell 7435.64% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 7435.64%. This contributed to the annual value of $56.4 million for FY2024, which is 3663.41% up from last year.
  • Per Precision Biosciences' latest filing, its Invested Capital stood at $16.6 million for Q3 2025, which was down 7435.64% from $34.1 million recorded in Q2 2025.
  • Over the past 5 years, Precision Biosciences' Invested Capital peaked at $125.1 million during Q2 2022, and registered a low of $16.6 million during Q3 2025.
  • For the 5-year period, Precision Biosciences' Invested Capital averaged around $70.3 million, with its median value being $62.4 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 11079.57% in 2021, then plummeted by 7435.64% in 2025.
  • Over the past 5 years, Precision Biosciences' Invested Capital (Quarter) stood at $93.6 million in 2021, then decreased by 11.74% to $82.7 million in 2022, then plummeted by 50.07% to $41.3 million in 2023, then soared by 36.63% to $56.4 million in 2024, then plummeted by 70.5% to $16.6 million in 2025.
  • Its Invested Capital was $16.6 million in Q3 2025, compared to $34.1 million in Q2 2025 and $49.3 million in Q1 2025.